Results 1 to 10 of about 18,764 (290)

Delivery and Biosafety of Oncolytic Virotherapy

Frontiers in Oncology, 2020
In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy. Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self-replication and antitumor immunity responses, showing great potential for ...
Lizhi Li, Lizhi Li, Shixin Liu, Shixin Liu, Duoduo Han, Duoduo Han, Bin Tang, Bin Tang, Jian Ma, Jian Ma, Jian Ma   +10 more
doaj   +2 more sources

Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma. [PDF]

Nat Commun
Oncolytic viruses (OVs) hold promise for cancer treatment. However, the antitumor efficacy is limited. Microbiota plays a pivotal role in cancer treatment and its impact on oncolytic virotherapy is unknown.
Zhang J, Yang J, Luo J, Wu W, Luo H, Wei W, Lyu H, Wang Y, Yi H, Zhang Y, Fan Z, Lyu H, Kanakaveti VP, Qin B, Yuan P, Yang R, Zhang H, Zuo T, Felsher DW, Lee MH, Li K.   +20 more
europepmc   +2 more sources

Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: Oncolytic virotherapy (OV) is an innovative immunotherapy strategy. A comprehensive understanding of oncolytic viruses is essential for advancing research and clinical practice.
Poyee Lau, Long Liang, Xiang Chen, Jianglin Zhang, Hong Liu   +4 more
doaj   +2 more sources

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

Pharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji, Yuchen Wu, Andreas Albers, Meiyu Fang, Xu Qian   +4 more
doaj   +2 more sources

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

Frontiers in Immunology, 2023
IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB.
Rūta Veinalde, Gemma Pidelaserra-Martí, Gemma Pidelaserra-Martí, Gemma Pidelaserra-Martí, Coline Moulin, Coline Moulin, Chin Leng Tan, Chin Leng Tan, Theresa E. Schäfer, Na Kang, Claudia R. Ball, Claudia R. Ball, Jonas Leichsenring, Jonas Leichsenring, Albrecht Stenzinger, Lars Kaderali, Dirk Jäger, Dirk Jäger, Guy Ungerechts, Guy Ungerechts, Christine E. Engeland, Christine E. Engeland, Christine E. Engeland   +22 more
doaj   +2 more sources

Oncolytic virotherapy: basic principles, recent advances and future directions

Signal Transduction and Targeted Therapy, 2023
Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they are generally considered to have direct oncolysis and cancer immune effects.
Danni Lin, Yinan Shen, T. Liang
semanticscholar   +1 more source

Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response

Biomedicines, 2022
Poxviridae have developed a plethora of strategies to evade innate and adaptive immunity. In this review, we focused on the vaccinia virus E3 protein, encoded by the E3L gene. E3 is present within the Chordopoxvirinae subfamily (with the exception of the
Mateusz Szczerba, Sambhavi Subramanian, Kelly Trainor, Megan McCaughan, Karen V. Kibler, Bertram L. Jacobs   +5 more
doaj   +1 more source

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Nature Medicine, 2023
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral
F. Nassiri, V. Patil, L. Yefet, O. Singh, Jeffrey C. Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, M. Daras, T. Cloughesy, H. Colman, P. Kumthekar, Clark C. Chen, R. Aiken, M. Groves, S. Ong, R. Ramakrishna, M. Vogelbaum, S. Khagi, T. Kaley, J. Melear, D. Peereboom, Analiz Rodriguez, M. Yankelevich, S. Nair, V. Puduvalli, Kenneth D. Aldape, A. Gao, Álvaro López-Janeiro, Carlos E. De Andrea, M. M. Alonso, P. Boutros, J. Robbins, W. Mason, A. Sonabend, R. Stupp, J. Fueyo, C. Gomez-Manzano, F. Lang, G. Zadeh   +38 more
semanticscholar   +1 more source

Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference

Viruses, 2023
Virotherapy is a promising, novel form of cancer immunotherapy currently being investigated in pre-clinical and clinical settings. While generally well-tolerated, the anti-tumor potency of oncolytic virus-based monotherapies needs to be improved further.
Sophie C. Anker, Marie G. Szczeponik, Jan Dessila, Katia Dittus, Christine E. Engeland, Dirk Jäger, Guy Ungerechts, Mathias F. Leber   +7 more
doaj   +1 more source

Evaluation of a toxoid fusion protein vaccine produced in plants to protect poultry against necrotic enteritis [PDF]

PeerJ, 2019
Background Necrotic enteritis (NE) is caused by type A strains of the bacterium Clostridium perfringens. Total global economic losses to the poultry industry due to NE is estimated to be over two billion dollars annually.
Joseph G.L. Hunter, Shyra Wilde, Amanda M. Tafoya, Jamie Horsman, Miranda Yousif, Andrew G. Diamos, Kenneth L. Roland, Hugh S. Mason   +7 more
doaj   +2 more sources